Timetable
9 November 2026
| Title | Name | Time | Type |
| One Policy, Many Responses: Mapping European Strategies to U.S. Most-Favoured Nation Pricing | Brittany Darrow | 10:30-13:30 | Poster Session 1 |
| Unlocking The Value of Biologic Therapies in Multiple Myeloma: The Potential of On-Body Injectors to Improve Healthcare Efficiency and Service Delivery | Henry Fong | 10:30-13:30 | Poster Session 1 |
| HEOR Impact Cases Poster Tour | Chris Skedgel (moderator) | 11:30-12:15 | HEOR Impact Cases |
| Are Patient Values Genuinely Shaping Value Assessment, or Do They Remain Acknowledged but Underutilized? | Chris Skedgel (panellist) | 13:45-14:45 | Issue Panel |
| Prevention Pays Off: Adult Respiratory Immunisation and The Road to Universal Health Coverage in South Africa | Ellie Tunnicliffe | 16:00-19:00 | Poster Session 2 |
| Breathe Easy: The Environmental and Economic Case for Carbon-Minimal Inhalers | Grace Hampson | 16:00-19:00 | Poster Session 2 |
| Whole Health at Risk: Does EU Joint Clinical Assessment Conflict with Europe’s Antimicrobial Resistance Ambitions? | Matthias Hofer (moderator) | 16:45-17:45 | Issue Panel |
10 November 2026
| Title | Name | Time | Type |
| Convergence and the Transatlantic Bargain: US Pricing Reform, the EU Pharma Package, and What Either Means for Innovation and Access | Lotte Steuten (panellist) | 10:30-11:30 | Issue Panel |
| Biosimilar-Enabled Access and Repositioning (BEAR): A Framework for Lifecycle Assessment and Repositioning of Biologic Therapies Informed by Cross-Country Evidence and Stakeholder Recommendations | Paul Oyalo | 10:30-13:30 | Poster Session 3 |
| Opportunity Cost, or Opportunity Lost? Sacred Principle, Functional Fiction, or Evolving Concept in HTA? | Lotte Steuten (speaker) | 12:15-13:15 | Forum |
| Are HTA and Health Funding Systems Failing to Incentivise Investment in Disease Prevention? | Grace Hampson (panellist) | 13:45-14:45 | Issue Panel |
| NICE Optimised Decisions: What is the Impact on Patient Access? | Brittany Darrow | 16:00-19:00 | Poster Session 4 |
| Could a Higher Willingness-to-Pay for ‘Innovative’ Therapies in Cost Effectiveness HTAs Help Enable Europe to Retain R&D and Manufacturing? | Lotte Steuten (panellist) | 16:45-17:45 | Issue Panel |
11 November 2026
| Title | Name | Time | Type |
| Can We STEDI the Course? Antimicrobial Value Assessment at a Crossroads | Grace Hampson (panellist) | 08:00-09:00 | Issue Panel |
| The Annual Societal Value of Continuous Vaccination Investment: A Benefit Cost Analysis of Adult Immunisation Programs in Germany | Matthew Napier | 09:00-11:30 | Poster Session 5 |